Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Vemliver from Entecavir in Chronic Hepatitis B
NCT06000657Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Daewoong Pharmaceutical. Started Aug 2023; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06000657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000657.